Targeting angiogenic metabolism in disease

See allHide authors and affiliations

Science  23 Mar 2018:
Vol. 359, Issue 6382, pp. 1335-1336
DOI: 10.1126/science.aar5557

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Blood vessels, which are lined by endothelial cells (ECs), supply oxygen and nutrients to every cell in the body. When tissues (or tumors) grow, they stimulate ECs to form new blood vessels (angiogenesis), so that they become better nourished. Hence, inhibiting angiogenesis to starve tumors has become a clinically approved therapy. For more than 40 years, antiangiogenic medicine has focused on targeting angiogenic signaling proteins, such as vascular endothelial growth factor (VEGF). However, the success of VEGF-targeted therapy for cancer and neovascular ocular diseases is limited by insufficient efficacy and/or drug resistance, necessitating a fundamentally different approach. Targeting EC metabolism is gaining increasing attention as a possible alternative for inhibiting angiogenesis.